Amended Statement of Beneficial Ownership (sc 13d/a)
December 17 2018 - 6:09AM
Edgar (US Regulatory)
|
OMB APPROVAL
|
|
OMB Number: 3235-0145
Expires: February 28, 2009
Estimated average burden
hours per response… 10.4
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of
1934
(Amendment No. 2)*
Ra
Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par
value $0.001 per share
(Title of Class of Securities)
74933V108
(CUSIP Number)
RA Capital Management, LLC
20 Park Plaza, Suite 1200
Boston, MA 02116
Telephone: 617.778.2512
Attn: Peter Kolchinsky
(Name, Address and Telephone Number of Person
Authorized to
Receive Notices and Communications)
December 12, 2018
(Date of Event Which Requires Filing of
this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. [ ]
Note:
Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to
be sent.
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 74933V108
1
|
Names of Reporting Persons.
RA Capital Healthcare Fund, L.P.
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
(a) [ ]
|
|
(b) [ ]
|
3
|
SEC Use Only
|
4
|
Source of Funds (See Instructions):
WC
|
5
|
Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):
[ ]
|
6
|
Citizenship or Place of Organization.
Delaware
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7 Sole Voting Power
0 shares
|
8 Shared Voting Power
3,971,750 shares
|
9 Sole Dispositive Power
0 shares
|
10 Shared Dispositive Power
3,971,750 shares
|
11
|
Aggregate Amount Beneficially Owned by
Each Reporting Person
3,971,750 shares
|
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ]
|
13
|
Percent of Class Represented by Amount
in Row (11)
9.7%
1
|
14
|
Type of Reporting Person (See Instructions)
PN (Limited Partnership)
|
1
The reporting person is the beneficial
owner of 3,971,750 shares of the Issuer’s Common Stock which constitute approximately 9.7% of the class outstanding. The
percentage calculation assumes that there are currently 40,774,123 outstanding shares of Common Stock of the Issuer as reported
in the Issuer’s prospectus filed with the Securities and Exchange Commission (“SEC”) on December 12, 2018.
CUSIP No. 74933V108
1
|
Names of Reporting Persons.
RA Capital Management, LLC
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
(a) [ ]
|
|
(b) [ ]
|
3
|
SEC Use Only
|
4
|
Source of Funds (See Instructions):
AF
|
5
|
Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):
[ ]
|
6
|
Citizenship or Place of Organization.
Massachusetts
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7 Sole Voting Power
0 shares
|
8 Shared Voting Power
4,858,260 shares
|
9 Sole Dispositive Power
0 shares
|
10 Shared
Dispositive Power
4,858,260 shares
|
11
|
Aggregate Amount Beneficially Owned by
Each Reporting Person
4,858,260 shares
|
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ]
|
13
|
Percent of Class Represented by Amount
in Row (11)
11.9%
2
|
14
|
Type of Reporting Person (See Instructions)
IA, OO (Limited Liability Company)
|
2
The
reporting person is the beneficial owner of 4,858,260 shares of the Issuer’s Common Stock which constitute approximately
11.9% of the class outstanding. The percentage calculation assumes that there are currently 40,774,123 outstanding shares of Common
Stock of the Issuer as reported in the Issuer’s prospectus filed with the Securities and Exchange Commission (“SEC”)
on December 12, 2018.
CUSIP No. 74933V108
1
|
Names of Reporting Persons.
Peter Kolchinsky
|
2
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
(a) [ ]
|
|
(b) [ ]
|
3
|
SEC Use Only
|
4
|
Source of Funds (See Instructions):
AF
|
5
|
Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):
[ ]
|
6
|
Citizenship or Place of Organization.
United
States
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
|
7 Sole Voting Power
0 shares
|
8 Shared Voting Power
4,858,260 shares
|
9 Sole Dispositive Power
0 shares
|
10 Shared
Dispositive Power
4,858,260 shares
|
11
|
Aggregate Amount Beneficially Owned by
Each Reporting Person
4,858,260 shares
|
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ]
|
13
|
Percent of Class Represented by Amount
in Row (11)
11.9%
3
|
14
|
Type of Reporting Person (See Instructions)
HC, IN
|
3
The reporting person is the beneficial
owner of 4,858,260 shares of the Issuer’s Common Stock which constitute approximately 11.9% of the class outstanding. The
percentage calculation assumes that there are currently 40,774,123 outstanding shares of Common Stock of the Issuer as reported
in the Issuer’s prospectus filed with the Securities and Exchange Commission (“SEC”) on December 12, 2018.
CUSIP No. 74933V108
This Amendment No. 2 amends and supplements
the statement on Schedule 13D (the “Statement”) originally filed with the Securities and Exchange Commission on November
9, 2016 by the Reporting Persons with respect to the Common Stock, $0.001 par value (the “Common Stock”), of Ra Pharmaceuticals,
Inc. (the “Issuer”). Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall
have the meanings ascribed to them in the initial Statement.
|
Item 3.
|
Source and Amount of Funds or Other Consideration
|
Item 3 of the Statement is hereby amended
and supplemented as follows:
On December 12, 2018, the Reporting Persons
purchased 1,006,452 shares of Common Stock of the Issuer for $15,600,006.00. The shares were purchased with working capital.
|
Item 4.
|
Purpose of Transaction
|
Item 4 is hereby supplemented as follows:
The Reporting Persons acquired the Common
Stock referred to in Item 3 for investment purposes and not with an intent, purpose or effect of changing control of the Issuer.
|
Item 5.
|
Interest in Securities of the Issuer
|
(a) and (b) See Items 7-11 of the cover
pages and Item 2 above.
(c) The following table lists the Reporting
Persons’ transactions in Common Stock that were effected during the sixty day period prior to the filing of this Schedule
13D:
Transaction
|
Date
|
No. Shares
|
Price
|
Purchase
|
12-Dec-2018
|
836,666* and 169,786
|
$15.50
|
Shares marked with an * were acquired by
the Fund. The remaining shares were acquired for the Account.
(d) Not applicable.
(e) Not applicable.
|
Item 7.
|
Material to Be Filed as Exhibits
|
Exhibit 1 Joint
Filing Agreement by and among the Reporting Persons is incorporated herein by reference to Exhibit 1 to the Schedule 13D filed
by the Reporting Persons with the Securities and Exchange Commission on November 9, 2016.
CUSIP No. 74933V108
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: December 14, 2018
RA CAPITAL HEALTHCARE FUND, L.P.
By: RA Capital Management, LLC
General Partner
By:
/s/ Peter Kolchinsky
Peter Kolchinsky
Manager
RA CAPITAL MANAGEMENT, LLC
By:
/s/ Peter Kolchinsky
Peter Kolchinsky
Manager
PETER KOLCHINSKY
/s/ Peter Kolchinsky
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Sep 2023 to Sep 2024